Type 2 diabetes
Conditions
Interventions
At the time of an FDG-PET / MRI examination pre-determined in routine medical care, we additionally take an MR enterography.
Sponsors
Kobe University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes 2. Patients taking metformin hydrochloride 3. Patients who have been determined to take an FDG-PET / MRI by routine medical care 4. Patients with no obvious lesions in the lower gastrointestinal tract 5. Patients aged 20 years or older at the time of consent 6. Patients who have given their informed consent to participate in this study
Exclusion criteria
Exclusion criteria: 1. Patients who participated in other clinical trials within 4 months 2. Patients suffering from dementia or psychiatric disorders 3. Patients with possible intestinal perforation or obstruction 4. Other patients judged inappropriate by the person in charge of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of excretion of FDG into the intestinal lumen | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between FDG excretion and various clinical parameters such as HbA1c and blood glucose level | — |
Countries
Japan
Contacts
Public ContactJun Ito
Kobe University Graduate School of Medicine Department of Internal Medicine Division of Diabetes and Endocrinology
Outcome results
None listed